Market Overview

Benzinga's Top Initiations

Related SNTS
UPDATE: Stifel Downgrades Santarus Following SLXP Acquisition
Benzinga's Top Downgrades
Related SLXP
Salix Secures Additional Intellectual Property Relating To Rifaximin
UCERIS 2mg Rectal Foam For The Induction Of Remission Of Mild-To-Moderate Distal Ulcerative Colitis Granted Tentative Approval By FDA

Janney Capital initiated coverage on shares of Salix Pharmaceuticals (NASDAQ: SLXP) with a “buy” rating. The target price for Salix is set to $55. Salix's shares closed at $47.21 yesterday.

Analysts at Leerink initiated coverage on shares of Santarus (NASDAQ: SNTS) with a “outperform” rating. Santarus' shares closed at $12.93 yesterday.

JP Morgan initiated coverage on shares of Infinity Pharmaceuticals (NASDAQ: INFI) with an “overweight” rating. The target price for Infinity Pharmaceuticals is set to $42. Infinity Pharmaceuticals' stock closed at $33.37 yesterday.

Analysts at Janney Capital initiated coverage on shares of Forest Laboratories (NYSE: FRX) with a “buy” rating. The target price for Forest Labs is set to $45. Forest Labs' shares closed at $36.28 yesterday.

Latest Ratings for SNTS

DateFirmActionFromTo
Dec 2013Stifel NicolausDowngradesBuyHold
Nov 2013Roth CapitalDowngradesBuyNeutral
Nov 2013Piper JaffrayDowngradesOverweightNeutral

View More Analyst Ratings for SNTS
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (INFI + FRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters